Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan
Despite high early persistence with somatropin, many children with pGHD in Japan were increasingly non-persistent over time: at 48 months post-index, at least 16% of children discontinued therapy, using the JDMC database and the most conservative measure of gap allowance. These results suggest a need for new strategies to support somatropin medication use over time among children with pGHD in Japan.
Authors
- Darrin Benjumea (ORCID: https://orcid.org/0000-0002-4537-1863)
- Kei Takasawa (ORCID: https://orcid.org/0000-0001-6947-4034)
- Jenifer Wogen
- Jane Loftus (ORCID: https://orcid.org/0000-0002-2374-8607)
- Michael P. Wajnrajch (ORCID: https://orcid.org/0000-0002-8211-9237)
- Yong Chen (ORCID: https://orcid.org/0009-0006-9094-7012)
- Priti Jhingran
- José Alvir
Institutions
- Tokyo Medical and Dental University (JP)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- New York University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1371/journal.pone.0324728
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00